CFDE Data Portal | Search LINC01798

	Label	Description
	LINC01798 Gene (Entity type)	ENSG00000232046 - long intergenic non-protein coding RNA 1798
	GSE220806 progesterone fibroblast 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 0 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE139178 GDC-0068 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 14 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE209698 calcitriol D 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 2 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 14 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE173201 cisplatin 2 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE162892 ISOX 3 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

LINC01798

ENSG00000232046 - long intergenic non-protein coding RNA 1798

GSE220806 progesterone fibroblast 1 v 3 human dn

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 0 v 7 human up

A Gene Set from LINCS

GSE139178 GDC-0068 3 v 1 human dn

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 14 v 7 human up

A Gene Set from LINCS

GSE209698 calcitriol D 2 v 1 human up

A Gene Set from LINCS

GSE195568 palbociclib 2 v 4 human dn

A Gene Set from LINCS

GSE111247 temozolomide LN-308 14 v 6 human up

A Gene Set from LINCS

GSE173201 cisplatin 2 v 3 human up

A Gene Set from LINCS

GSE162892 ISOX 3 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.